Tristetraprolin: A novel target of diallyl disulfide that inhibits the progression of breast cancer

20Citations
Citations of this article
18Readers
Mendeley users who have this article in their library.

Abstract

Diallyl disulfide (DADS), a volatile component of garlic oil, has various biological properties, including anti-oxidant, antiangiogenic and anticancer effects. The present study aimed to explore novel targets of DADS that may slow or stop the progression of breast cancer. First, xenograft tumor models were created by subcutaneously injecting MCF-7 and MDA-MB-231 breast cancer cells into nude mice. Subsequently, western blot analysis was performed to investigate the expression of tristetraprolin (TTP), urokinase-type plasminogen activator (uPA) and matrix metalloproteinase-9 (MMP-9) in the xenograft tumors, and cell cultures. Tablet cloning, Transwell and wound healing assays revealed that DADS treatment significantly inhibited the proliferation, invasion and migration of breast cancer cells. In addition, DADS treatment led to significant downregulation of uPA and MMP-9 protein expression, but significantly upregulated TTP expression in vivo and in vitro. Knocking down TTP expression using small interfering RNA reversed the aforementioned effects of DADS, which suggests TTP is a key target of DADS in inhibiting the progression of breast cancer.

Cite

CITATION STYLE

APA

Xiong, T., Liu, X. W., Huang, X. L., Xu, X. F., Xie, W. Q., Zhang, S. J., & Tu, J. (2018). Tristetraprolin: A novel target of diallyl disulfide that inhibits the progression of breast cancer. Oncology Letters, 15(5), 7817–7827. https://doi.org/10.3892/ol.2018.8299

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free